Does Xiidra (lifitegrast) have a known “ophthalmic expiry date”?
A specific “ophthalmic expiry date” is usually shorthand for when patent protections (or other exclusivity rights) stop blocking generic or biosimilar versions. For Xiidra (lifitegrast ophthalmic solution), that timing depends on the relevant patent(s) and the jurisdiction, and it is not captured by a single universal date.
The information needed to state an exact expiry date (for example, the specific U.S. Orange Book entry with its listed patent numbers and their expiration dates, or equivalent records in other countries) is not included in the materials available here.
What’s the most reliable way to find the actual patent expiration date for Xiidra?
Search the official drug protection record for your country/region and identify:
- the exact product (brand vs. strength/formulation),
- the listed patent(s) tied to that product, and
- the expiration date for each patent (not one generic “expiry” value).
In the U.S., this is typically done via the FDA’s Orange Book records for Xiidra; in Europe, via national/regional patent and supplementary protection certificates; and in other regions via their regulator/patent registries.
Why can there be multiple dates (and multiple patents) for the same eye drug?
Even one branded ophthalmic drug can be covered by several layers of protection:
- compound-related patents (covering the molecule),
- formulation/device/packaging patents,
- method-of-use patents,
- regulatory exclusivities (which are not the same thing as patent expiration).
That’s why different sources may show different “expiry” dates depending on whether they mean patent expiry, exclusivity expiry, or the first date generic competition is allowed.
Can a generic enter before “lifitegrast” patents fully expire?
Yes, potentially. A generic (or an authorized follow-on product) can sometimes launch before the last patent expires if:
- it is cleared under regulatory pathways that allow entry against patents that are no longer enforceable or not listed for that specific regulatory approval, or
- certain patents have already expired or are found not to block approval for that applicant’s product.
The exact timing for Xiidra depends on the patent-by-patent and jurisdiction-by-jurisdiction status.
What do you need from me to pin down the exact expiry date?
If you tell me:
- the country (e.g., U.S., UK, EU, Canada),
- whether you mean patent expiry or regulatory/exclusivity expiry,
- and the strength (Xiidra is commonly listed by concentration),
I can help you locate the correct record format and identify which listed date corresponds to the “expiry” you’re asking about.
Sources
No sources were provided in the prompt.